Head-to-head evidence
Lacosamide vs Zonisamide (Zonegran)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels · full Epilepsy pipeline
Lacosamide
Marketed by UCB
NCT00136019 · Phase 3 · completed
Although the study was described as randomized and double-blind with an estimated 400 participants, the registry lists only the lacosamide intervention and no comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Zonisamide (Zonegran)
Marketed by Advanz Pharma and partners
NCT00056576 · Phase 3 · completed
Although 165 participants were reportedly randomized and treatment was double-blinded, the study is listed as a single-group design with no placebo or active comparator. No primary endpoint or results are posted, so whether the primary outcome was met or missed cannot be assessed.
Next expected readout: July 2027 · NCT06967012 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lacosamide's landscape · Zonisamide (Zonegran)'s landscape